NC
NVCR icon

nVerses Capital’s NovoCure NVCR Stock Holding History

nVerses Capital’s Portfolio NVCR Stock Details NVCR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-7,200
Closed -$113K – 590
2024
Q3 		$113K Sell
7,200
-900
-11% -$16.3K 0.05% 457
2024
Q2 		$139K Buy
8,100
+4,300
+113% +$75.6K 0.08% 350
2024
Q1 		$59.4K Buy
+3,800
New +$55.9K 0.14% 254

Other funds holding NVCR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

nVerses Capital's NVCR Position: Q4 2024 in Review

nVerses Capital sold out of NovoCure (NVCR) in Q4 2024, closing a stake of 7,200 shares — an estimated $113K sold.

nVerses Capital first reported a position in NVCR in Q1 2024 and held it in 3 quarters. The position peaked at $139K in Q2 2024. 238 funds tracked by Wall St. Rank hold NVCR as of Q4 2024.

  • nVerses Capital reported no remaining NovoCure position as of Q4 2024 after selling out during the quarter.
  • nVerses Capital sold 7,200 NovoCure shares in Q4 2024, an estimated $113K.
  • nVerses Capital first reported a position in NovoCure in Q1 2024 and held it in 3 quarters.
  • nVerses Capital's NovoCure position peaked at $139K in Q2 2024.
  • 238 funds tracked by Wall St. Rank held NovoCure as of Q4 2024.

Based on nVerses Capital's 13F filing for Q4 2024.